New research has shown that enhancer of zeste homolog 2 (EZH2) is activated or overexpressed by mutations in melanoma and other tumors, resulting in the silencing of antigen presentation-related genes and cancer suppressor genes [61]. This evidence concerns the gene EZH2 and melanoma.